Fairvalue-Calculator Fairvalue-Calculator
EN DE

SCYNEXIS, Inc (SCYX) Fair Value & Analysis

Healthcare · US · Market cap $40.2M

Price$3.87
Fair Value$16.86
Upside+335.7%
Quality95/100
Evidence: Low Range $8.65 – $24.97

Fair value as of: Jun 25, 2026

Analysis

SCYNEXIS, Inc (SCYX) currently trades at $3.87, while our model-based Fair Value estimate is $16.86 — implying the stock looks roughly 335.7% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.

About the company

SCYNEXIS, Inc., a biotechnology company, engages in drug development for the treatment and prevention of difficult-to-treat and drug-resistant fungal infections in the United States. The company offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis and for the reduction in the incidence of recurrence. It also develops SCY-247, which is in Phase I clinical trial for the treatment of invasive fungal infections. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.

Open the full interactive analysis →

Similar stocks

Takeda Pharmaceutical Company (TAKP34) +3193% Jiangsu Hengrui Pharmaceuticals Co (600276) -37% Sun Pharmaceutical Industries Limited (SUNPHARMA) -44% Zoetis Inc (Z1TS34) -1% Hansoh Pharmaceutical Group (3692) -37% Divi's Laboratories Limited (DIVISLAB) -70%

Frequently asked questions

Is SCYNEXIS, Inc (SCYX) undervalued?
As of Jun 25, 2026, our model estimates a fair value of $16.86 versus a price of $3.87 — about +336% (undervalued). Model-based estimate, not financial advice.
What is the fair value of SCYX?
Our 21-model fair value for SCYNEXIS, Inc is $16.86 (as of Jun 25, 2026), built from audited fundamentals. The current price is $3.87.
What is the quality score of SCYX?
SCYNEXIS, Inc has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.